An interventional study of Lateral Quadratus Lumborum Block and ıv morphine PCA in Anesthesia, Postoperative Pain and Regional Anesthesia, sponsored by Ondokuz Mayıs University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Pain, Postoperative by Ondokuz Mayıs University — 8 open to participants now, 8 under way, none of them phase 3. Pain, Postoperative · Ondokuz Mayıs University.
Among the 29 studies in Pain, Postoperative by Ondokuz Mayıs University, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2026, is one of 24 with no phase, and was the 25th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 29 studies in Pain, Postoperative by Ondokuz Mayıs University are open now, in 1 country. Recruiting first, the newest first:
Ondokuz Mayıs University · Sites in Turkey
Ages 18+ · Women only
Ondokuz Mayıs University · Sites in Turkey
Ages 18+
Ondokuz Mayıs University · Sites in Turkey
Ages 18–80
Ondokuz Mayıs University · Sites in Turkey
Ages 18+
Ondokuz Mayıs University · Sites in Turkey
Ages 18–80
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 69 across the 24 interventional studies, 60 across the 5 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.
7 of the studies in Pain, Postoperative by Ondokuz Mayıs University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07164677Ondokuz Mayıs UniversitySerratus Posterior Superior Plane Block for Postoperative Pain in Cardiac Surgery | 2026-12-01 |
| NCT07712783Ondokuz Mayıs UniversityLateral QL Block vs Intrathecal Morphine for Cesarean Section | 2027-01-01 |
| NCT07449273Ondokuz Mayıs UniversityBreathing Interventions for Postoperative Breast Surgery Patients | 2027-02-27 |
| NCT07778355Ondokuz Mayıs UniversityOrientation Video Training Administered at Different Times to Patients Undergoing Prostate Surgery on Postoperative Pain and Anxiety (Video Training) | 2027-03-01 |
| NCT07898020Ondokuz Mayıs UniversityUreteral Access Strategies in Retrograde Intrarenal Surgery | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 29 studies in Pain, Postoperative by Ondokuz Mayıs University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effective postoperative analgesia after cesarean delivery is essential for maternal recovery, early mobilization, breastfeeding, and maternal-infant bonding. Although intrathecal morphine (ITM) is considered the gold standard for post-cesarean analgesia, its use is associated with opioid-related adverse effects. Ultrasound-guided lateral quadratus lumborum block (QLB-I) has emerged as a promising alternative. This randomized, double-blind, non-inferiority trial aims to compare the postoperative analgesic efficacy of lateral QLB-I with ITM. Secondary outcomes include postoperative opioid consumption, pain scores, opioid-related adverse effects, quality of recovery (ObsQoR-11T), and maternal satisfaction.
Effective postoperative analgesia following cesarean delivery is essential not only for improving maternal comfort but also for facilitating early mobilization, breastfeeding, and maternal-infant bonding. Inadequate pain control has been associated with delayed mobilization, pulmonary complications, postpartum depression, and the development of chronic postsurgical pain (CPSP).
Intrathecal morphine (ITM) has long been regarded as the gold standard for post-cesarean analgesia, providing effective pain relief for 18-24 hours after a single dose. However, its use is limited by opioid-related adverse effects, including pruritus, postoperative nausea and vomiting (PONV), sedation, and urinary retention. These adverse effects may reduce maternal satisfaction and negatively affect breastfeeding and early mobilization.
In recent years, quadratus lumborum block (QLB) has emerged as an effective alternative for postoperative analgesia in abdominal surgery. Among the various QLB approaches, the lateral QLB-I technique has attracted considerable interest because of its ease of ultrasound-guided application, low incidence of motor block, and potential to provide extensive visceral and somatic analgesia. Previous studies have demonstrated that QLB can effectively attenuate both somatic and visceral pain, with cranial spread of local anesthetic along the thoracolumbar fascia reaching the ventral rami of the thoracic nerves (Blanco, 2015; Elsharkawy, 2019).
Randomized controlled trials in patients undergoing cesarean delivery have shown that QLB reduces postoperative opioid consumption, lowers pain scores, and improves patient satisfaction compared with control groups (Salama, 2020; Zhu, 2021). However, studies directly comparing QLB with ITM remain limited. Current evidence suggests that the analgesic efficacy of QLB may be comparable to that of ITM, although robust evidence demonstrating non-inferiority is still lacking.
Compared with ITM, the principal advantages of lateral QLB include the absence of motor blockade, the potential to reduce opioid-related adverse effects, and facilitation of early mobilization. Although ITM provides potent analgesia, demonstrating that the analgesic efficacy of lateral QLB is clinically equivalent within a non-inferiority margin not exceeding 10 mg intravenous morphine milligram equivalents (IV-MME) would represent a clinically acceptable outcome in terms of patient comfort and safety.
Accordingly, the primary objective of this study is to determine whether lateral QLB-I provides non-inferior postoperative analgesia compared with ITM. Secondary objectives include a comprehensive evaluation of adverse effects, quality of recovery using the ObsQoR-11T, and postoperative opioid consumption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LQLB (Active) + Sham ITM
Procedure: Lateral Quadratus Lumborum Block · Drug: ıv morphine PCA
ITM (Active) + Sham QLB
Drug: ıv morphine PCA · Procedure: Intrathecal morphine
Active Lateral QLB Local anesthetic: 0.25% bupivacaine, 0.4 mL/kg perside (maximum 30 mL per side). Maximum total dose: Bupivacaine ≤2.5 mg/kg (maximum approximately 150 mg). Timing: Immediately after completion of surgery. The patient will be positioned supine or in a slight lateral decubitus position. A high-frequency linear US transducer (5-12 MHz) will be placed on the anterolateral abdominal wall at the T12-L1 level. The fascial plane will be identified under ultrasound guidance. A 22-gauge, 100-mm needle will be advanced using an in-plane approach, and after negative aspiration, the local anesthetic will be injected incrementally with hydrodissection confirming correct spread. Sham ITM: The spinal anesthesia technique will be identical to that of the active ITM group. Morphine will be replaced with 0.2 mL preservative-free normal saline, while maintaining an identical syringe volume (2.7 mL) and appearance.
Also known as: Lateral QLB
A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/ kg (IBW). No basal infusion will be used.
Also known as: PCA
Hyperbaric 0.5% bupivacaine 12.5 mg, fentanyl 20 µg, and morphine 80 µg (0.08 mg). Spinal anesthesia will be performed at the L3-L4 or L4-L5 intervertebral space using a 25-gauge Quincke spinal needle. The study solution will be prepared to a total volume of 2.7 mL. Sham QLB Following completion of surgery, the patient will be positioned in the lateral decubitus position. The ultrasound transducer will be placed over the lateral QLB scanning window. A 22-gauge needle will be advanced into the skin and subcutaneous tissue only, without entering the fascial plane. To maintain procedural standardization and preserve blinding, 1-2 mL of normal saline will be injected into the subcutaneous tissue. Procedure duration, patient positioning, ultrasound probe placement, and dressing application will be identical to those used for the active lateral QLB-I procedure. A sterile dressing will be applied at the end of the procedure.
Also known as: ITM
Cumulative equivalent morphine consumption in the first 24 hours after surgery
The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 24 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.
Time frame: postoperative day 1
Cumulative equivalent morphine consumption in the first 48 hours after surgery
The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 48 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.
Time frame: postoperative day 2
Cumulative equivalent morphine consumption in the first 12 hours after surgery
The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 12 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.
Time frame: postoperative day 1
Postoperative pain scores
Pain status at rest and while activity will be assessed by NRS score at 0, 3, 6, 12, 24,36 and 48. hours after surgery. The NRS is an 11-point numeric scale that ranges from 0 to 10.
Time frame: postoperative day 2
area under the NRS score curve (AUC) for resting
area under the NRS score curve (AUC) for resting and active 48 hours after surgery
Time frame: postoperative day 2
Integrated Analgesic Score
Composite outcome integrating pain burden (AUC) and opioid consumption (IV-MME), expressed as the Integrated Analgesia Score (IAS), with lower scores indicating better overall analgesic efficacy.
Time frame: postoperative day 2
Effective Analgesic Score
The Integrated Analgesia Score (IAS) will be calculated by jointly evaluating the mean pain scores (NRS, 0-10) and cumulative intravenous morphine milligram equivalent (IV-MME, mg) consumption over the 0-48-hour postoperative period.
Time frame: postoperative day 2
Time of first analgesic request
Time at which the first analgesic is requested
Time frame: postoperative day 1
The number of patients requiring rescue analgesics
The number of patients requiring rescue analgesics will be recorded over 24 hours.
Time frame: postoperative day 1
ObsQoR-11T (Obstetric Quality of Recovery) score
A validated patient-reported outcome measure assessing the quality of postoperative recovery after cesarean delivery. The questionnaire consists of 11 items evaluating pain, physical comfort, physical independence, emotional state, and the ability to care for the newborn, with higher scores indicating better quality of recovery. Scores range from 0 to 110, with higher scores indicating better recovery. Assessments will be performed preoperatively (baseline) and at 24 and 48 hours postoperatively.
Time frame: postoperative day 2
The number of patients requiring postoperative antiemetics.
The number of patients requiring treatment and PONV scores will be recorded in the post-anesthesia care unit (PACU) and at 3, 6, 12, 24, 36, and 48 hours postoperatively. PONV will be assessed using a 4-point scale: 0 = no nausea or vomiting; 1 = mild nausea; 2 = one episode of vomiting; and 3 = more than one episode of vomiting.
Time frame: postoperative day 2
The incidences of post-operative pruritus
The presence and severity of pruritus will be assessed using a four-point scale where 0 indicates no pruritus, 1 indicates mild pruritus, 2 indicates moderate pruritus, and 3 indicates severe pruritus. A score of ≥1 will be considered the presence of pruritus.
Time frame: postoperative day 2
Sedation score
Sedation levels will be assessed using the Pasero Opioid-Induced Sedation Scale (POSS) and recorded during the first 48 postoperative hours in the post-anesthesia care unit (PACU) and at 3, 6, 12, 24, 36, and 48 hours postoperatively. Sedation will be graded as follows: S = awake and alert; 1 = slightly drowsy, easily aroused; 2 = frequently drowsy, easily aroused, drifts off to sleep during conversation; 3 = somnolent, difficult to arouse; and 4 = minimal or no response to verbal or physical stimulation. Opioid-induced sedation will be defined as a POSS score ≥3 or a respiratory rate \<8 breaths/min.
Time frame: postoperative day 2
The incidences of Urinary retention
Number of patients with urinary retention (defined as failure to achieve spontaneous voiding within 8 hours after Foley catheter removal)
Time frame: postoperative day 2
The morbidity of patients
The patients comorbidities will be assessed using the Charlson Comorbidity Index
Time frame: Postoperative 1 month on an average
The number of patients with complications
The number of patients has any complications -directly related to the block or the drug used in the block- will be recorded
Time frame: Postoperative 1 month on an average
Delayed onset of lactation
Delayed onset of lactation will be defined as the maternal report of milk coming in (based on subjective breast fullness and the transition from colostrum to mature milk) occurring more than 48 hours after delivery.
Time frame: postoperative day 2
Apgar scores
Apgar scores at 1 and 5 minutes will be recorded. In addition, the need for neonatal intensive care unit (NICU) admission and any requirement for additional neonatal resuscitation will be documented.
Time frame: postoperative day 1
Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2026 → Jan 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.